Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2SRG1
|
|||
| Drug Name |
PF-07209326
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | E-selectin (SELE) | Target Info | Antagonist | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| TNF signaling pathway | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| ID Signaling Pathway | ||||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Glucocorticoid receptor regulatory network | ||||
| ATF-2 transcription factor network | ||||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Human Complement System | |||
| TNF alpha Signaling Pathway | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.